PROBALAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Probalan, and what generic alternatives are available?
Probalan is a drug marketed by Lannett and is included in one NDA.
The generic ingredient in PROBALAN is probenecid. There are ten drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the probenecid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Probalan
A generic version of PROBALAN was approved as probenecid by WATSON LABS TEVA on March 29th, 1983.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PROBALAN?
- What are the global sales for PROBALAN?
- What is Average Wholesale Price for PROBALAN?
Summary for PROBALAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 5 |
| Patent Applications: | 2,517 |
| DailyMed Link: | PROBALAN at DailyMed |
Recent Clinical Trials for PROBALAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institutes of Health (NIH) | Early Phase 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Early Phase 1 |
| Washington State University | Early Phase 1 |
US Patents and Regulatory Information for PROBALAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett | PROBALAN | probenecid | TABLET;ORAL | 080966-001 | Approved Prior to Jan 1, 1982 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
